Jun 01, 2021 / 05:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
All right. Well, good afternoon, everyone, and thank you for joining me on this afternoon's session here today at the 2021 Jefferies Global Healthcare Conference. I'm really grateful to have with me Gilead, the Chairman of the Board and CEO, Dan O'Day; as well as the Chief Commercial Officer, Johanna Mercier. And there's plenty to talk about at Gilead.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystAnd so first, I would just love to maybe just start high level with Dan and maybe talk about a question and a topic that investors have on their mind, which is the word growth. And I think it seems to me that people struggle with whether Gilead is a growth company or how growthy and the different levers, I think, people are, I think, perplexed by.
So maybe you could just make a comment about, excluding perhaps Veklury, is Gilead going to grow this year and in '22 and '23? And maybe just what are the key levers that will do that? So
Trustpilot
